Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More
 

May 17, 2018

Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CAMay 15, 2018

May 15, 2018

Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain

May 9, 2018

Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test

May 8, 2018

Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test

April 17, 2018

Exosome Diagnostics Obviates Tissue Biopsies

March 21, 2018

Exosome Diagnostics Appoints Accomplished Urologist, Grannum Sant, MD, FRCS, FACS, as Head of Medical Affairs

March 20, 2018

Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients

March 13, 2018

Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor

February 23, 2018

Exosome Diagnostics Expands its Coverage Reach for EPI to an Additional 82 Million Covered Lives in the United States

February 1, 2018

Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed 

January 25, 2018

Exosome Diagnostics Executes Agreement with America’s Choice Provider Network Expanding Access and Coverage for EPI to 28 Million Member Network in the US

January 9, 2018

Exosome Diagnostics Places Early Access Shahky™ Exosomal Protein Detection System at MGH Center for Systems Biology

January 8, 2018

Exosome Diagnostics Announces Positive Coverage for EPI from Largest Payor in the Mid-Atlantic Region

January 8, 2018

Exosome Diagnostics Places Its First Early Access Shahky System within a Top 15 Pharmaceutical Laboratory

January 4, 2018

Exosome Diagnostics Launches National Sales Team to Support Flagship Test, ExoDx®Prostate(IntelliScore) 

December 19, 2017

Exosome Diagnostics Publishes a Study Demonstrating Superior Performance of ExoLution™ Plus Liquid Biopsy Platform in Lung Cancer

December 4, 2017

Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network

November 27, 2017

Exosome Diagnostics Announces National Medicare Reimbursement Rate Set at $760 for its Prostate Cancer IntelliScore Test

November 13, 2017

Exosome Diagnostics and Leading Academic Cancer Center Demonstrate Superior Liquid Biopsy Performance

October 11, 2017

Exosome Diagnostics to Present a Novel Atlas of Exosomal mRNA and Long non-coding RNA Across Biofluids at American Society of Exosomes and Microvesicles Annual Meeting

September 19, 2017

Exosome Diagnostics and Chesapeake Urology Partner to Evaluate Clinical Value of ExoDx® Prostate(IntelliScore) in First Study Under Novel Evidence Development Collaboration

August 9, 2017

Exosome Diagnostics Launches the MedOncAlyzer™ Pan-Cancer Panel

August 3, 2017

Exosome Diagnostics Achieves ISO 13485 Certification

August 1, 2017

Exosome Diagnostics Announces New World Headquarters and Laboratory in Waltham, MA

July 24, 2017

Exosome Diagnostics Completes $30 Million Series C Financing

June 22, 2017

Exosome Diagnostics Presents Breakthrough Liquid Biopsy Technologies at BIO International Convention

May 31, 2017

Exosome Diagnostics Will Demonstrate the “Shahky” Point of Care Protein Detection Instrument at American Society for Clinical Oncology

UPCOMING EVENTS

View more News and Events

Now available to Heathcare Providers for Clinical Use: The Industry’s First Exosome-Based Liquid Biopsy Tests

Order Here

The Industry’s First RNA-Based Liquid Biopsies

We are bringing the first exosome-based diagnostics to market. Learn more about our Laboratory Developed Tests, which will be analyzed in our CLIA-certified laboratory: